Prescribers Bulletin Index
Following is a list of Medicaid General and Special Bulletin articles (2000-present) that pertain specifically to Prescribers (Outpatient Pharmacy Program).
For a complete list of articles for all providers (including articles about National Provider Identifier) refer to the Index of All Medicaid Bulletins.
- "Medically Necessary" Replaces "Dispense as Written":
- 34-Day Grace Period for Prescription Drug PA, 7/02
- Allowable Days Supply to Change on Prescriptions, 7/01
- Behavioral Pharmacy Management Project, 12/06
- Benzodiazepines and Barbiturates are No Longer Covered for Dual Eligible Beneficiaries, 12/12, 1/13
- Changes to Prior Authorization Requirements for Antinarcolepsy/Antihyperkinesis Agents, 9/09
- Cialis, 2/04
- Clarification on Coverage of Birth Control Pills for Diagnosis Other than Contraception, 4/06
- Concurrent Use of Methadone and Benzodiazepines, 4/13
- Conversion from UPIN Numbers to DEA Numbers:
- Correction for Removal of Smoking Cessation Medications, 2/05
- Coverage of Over-the-Counter Medications, 12/03
- Coverage of Over-the-Counter Second Generation Antihistamine and Decongestant Combinations, 9/10
- Coverage of Prescription Vitamins and Mineral Products for N.C. Medicaid Recipient, 4/11
- Days Supply on Pharmacy Claims:
- DEA Number Required:
- Delay in Non-Enrolled Prescriber Edit, 3/13, 4/13
- Discontinuation of Coverage for Anorexia, Weight, Loss, and Weight Gain Products and Medications, 11/04
- Discontinuation of Coverage for Vioxx, 11/04
- Discontinuation of the 34-Day Grace Period for Prescription Drug PA for Long Term Care Facilities, 12/05
- Discontinuation of Focused Risk Management Program, 12/10
- Drug Utilization Review Intervention Letters, 3/11
- Drug Utilization Review Section, 9/00
- End-Dated Coverage for Exocrine Pancreatic Insufficiency Drugs, 6/10
- End-Dated Coverage of Generic Colchicine, 12/10
- Exemptions to Prescription Drug PA Criteria, 7/02
- Expansion in Coverage of Zelnorm in Males, 3/05
- Levitra, 11/03
- Limitations on Medicaid Services Provided to Hospice Recipients - Clarification of Policy, 8/05
- Long-Term Care Pharmacists May Seek Prescription Drug Prior Authorization, 7/02
- Medical Necessity Criteria for Approval of Provigil, 11/04
- N.C. Medicaid and N.C. Health Choice (NCHC) Preferred Drug List Changes, 11/12
- N.C. Medicaid Preferred Drug List Changes, 6/10
- N.C. Medicaid Upper Limits for Betaseron 0.3 mg, Migranal Nasal Spray and Torado/Ketolac 10mg Tablets, 3/06
- New Appeals Process Affecting Prior Authorized Medications, 11/08
- New Pharmacy Prior Authorization Program for Second Generation Antihistamines:
- New Prior Authorization Program for Brand-name Narcotics:
- New Prior Authorization Requirements for Brand-name ACE Inhibitors, Angiotensin Receptor Blockers, and Renin Inhibitors, 9/09
- New Prior Authorization
Requirements for Brand-Name Anticonvulsants, 1/10
- New Prior Authorization Requirements for Brand-name Fibrates and Lovaza:
- New Prior Authorization Requirements for Brand-name Muscle Relaxants, 8/09
- New Prior Authorization Requirements for Brand-name Nasal Steroids, 8/09
- New Prior Authorization Requirements for Incivek, Victrelis, Kalydeco, and Cialis, 11/12
- New Prior Authorization Requirements for Leukotriene Modifiers, 11/09
- New Prior Authorization Requirements for Serotonin 5-HT1 Receptor Agonists (Triptans), 8/09
- New Prior Authorization Requirements for Short-acting Inhaled Beta Agonists, 10/09
- New Prior Authorization
Requirements for Topical Anti-inflammatory Medications, 1/10
- New SmartPA Pharmacy Prior Authorization Program, 4/08
- Nicotine Products on the Over-the-Counter Coverage List 4/06
- Over-The Counter Nicotine Replacement Therapy Medications Covered by Medicaid, 10/05
- Oxycontin:
- Pharmacy Episodic Drug Policy – Quantity Limitations on Sedative Hypnotics, 4/06
- Pharmacy Seminars, 4/06
- Phase Two Policy Implementation, 8/11
- Plan B Product Coverage, 2/07
- Policies for Emend, Leukotrienes, Lidodrem, Orally Inhaled Corticosteroids, Statins, and Suboxone and Revised Policies for CII Narcotic Analgesics and Second Generation Anticonvulsants, 9/10
- Policy and Procedures for Prescribing Synagis:
- Policy Implementation: Off Label Antipsychotic Monitoring Children through Age 17, 4/11
- Prescribers not Enrolled in Medicaid, 12/12, 1/13, 2/13
- Prescription Advantage List Update, 7/05
- Prescription Limitations, 4/06
- ProAir Placed on Preferred Drug List (PDL), 4/13
- Proton Pump Inhibitors:
- Quantity Limits Put in Place for Oxycontin, 7/01
- Recipient Lock-In to One Pharmacy Per Month, 6/03
- Recommendations from Drug Utilization Review Study, 2/01
- Removal of Active Pharmaceutical Ingredients and Excipients as Covered Outpatient Drugs, 12/10
- Removal of ADHD Drugs and Rebetron from the Prior Authorization Drug List, 9/04
- Removal of Cough and Cold Medications from Coverage, 12/09
- Removal of Enbrel from the Authorization Drug List, 3/05
- Removal of Smoking Cessation Medications and Products from the Prior Authorization Drug List, 11/04
- Revised Prior Authorization Requirements for Leukotriene Modifiers, 11/12
- Senior Care Drug Assistance Program, 11/02
- Suboxone, Subutex, and Buprenorphine Prior Authorization, 1/11
- Substitution for Duoneb and Insulin Cartridges and Pens, 9/10
- Substitution of Preferred Brand Drugs, 9/10
- Tacrolimus Added to the Narrow Therapeutic Index List, 6/09
- Technical Correction to General Policy for Over the Counter Medications, 9/04
- Transition Period for Oral Inhaled Corticosteroids, Leukotrienes, and Statins, 3/11
- Upcoming Policy Implementation: Off Label AntipsychoticMonitoring in Children through Age 17, 3/11
- Update: Active Pharmaceutical Ingredients and Excipients, 3/11
- Updated Prescription Advantage List, 6/08
- Valid DEA Numbers Required on Pharmacy Prescriptions:
